Department of Defense: Congressionally Directed Medical Research Programs

Home - Site Map - Contact Us       

Department of Defense logo
Funding Innovation - Finding A Cure - Providing Hope
Department of Defense logo

Chronic Myelogenous Leukemia Research Program

Proposal Submission

Vision

To perfect the existing and develop new diagnostic and therapeutic approaches for chronic myelogenous leukemia.

Mission

To sponsor basic and clinically oriented research in the field of chronic myelogenous leukemia.


Image of a man watering his lawn.

Chronic myelogenous leukemia (CML) is also known as chronic granulocytic leukemia or chronic myeloid leukemia. CML is an overgrowth of granulocytes, a type of white blood cell; its cause is unknown. The disease accounts for about 20 percent of adult leukemias in Western countries. This year, approximately 5,050 individuals will be diagnosed with CML, and an estimated 470 will die from the disease. In most cases, CML is characterized by a chromosomal abnormality that is known as the Philadelphia chromosome. Treatment usually consists of various chemotherapeutic agents used to disrupt the production of leukemic cells. These treatments may be followed by stem cell transplant.


Congressional Appropriations


Funding Summary

  • 61 awards in FY02-06